EMA
withdrawal
· 2015-04-01
EMA Withdrawn: BindRen (colestilan) — Mitsubishi Pharma Europe Ltd
Summary
The EMA has withdrawn BindRen (colestilan) from the market in Europe.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Withdrawn. Therapeutic area: Hyperphosphatemia. MAH: Mitsubishi Pharma Europe Ltd. Decision date: 26/03/2015